Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (176)	11/11/1997 10:15:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

Back to more mundane matters.....I think the action looked fairly good today despite being down. Price swooned to well below 8, then closed virtually unchanged. Volume still looks ok. As long as the broader market can keep afloat IMHO IVX will continue to drift upward. Jackson

To: flickerful who wrote (176)	11/12/1997 4:42:00 PM
From: jpmac	Read Replies (1) \| Respond to of 756

this is from jackson's post #162... >>a) substantial insider buys at $13 - $15 with some follow up buying at 10. In a world of imperfect information, this is not to be ignored. Ivax is most likely fairly valued somewhere around $13 - $14/share<<

To: flickerful who wrote (176)	11/12/1997 11:26:00 PM
From: 5,17,37,5,101,...	Respond to of 756

The action looked OK today despite being down. Notice S&P futures are up nicely in aftermarket. People (Bergsten ??) are beginning to talk of massive bailouts for these banana economies which may shore things up long enough for Ivx to .... dare I say it. No I won't. Good luck, Jackson

To: flickerful who wrote (176)	11/18/1997 7:05:00 PM
From: John McCarthy	Respond to of 756

Randy, Read NPRO ... don't know the SOURCE of this. John

To: flickerful who wrote (176)	11/19/1997 6:39:00 AM
From: 5,17,37,5,101,...	Read Replies (2) \| Respond to of 756

I have a call into Mr. Jaffe at IR to determine the mood at IVX, among other things. So far he has not returned my call. Upon study of cash flow statements, it appears IVX may have somewhere in the neighborhood of $75 to $100 mill cash flow from operations for year ended 12/31/97. This represents about a 8 to 10 year payoff (not NetPresentValue but close enough). Based on this I think IVX is fairly valued around $9 or $10/share, Excluding Paxene sales if approved. Paxene sales should percolate mostly to the bottom line which should increase cash flow from operations nicely. If Paxene sales total $242 mill next year, roughly 25% of present market (see BM-S exerpt from 11/97 10Q) which is growing at 18% (or more because BM-S Taxol was recently approved for K-S), then I think cash flow will increase by at least 10% of that to ~$125 or about a $1.00 per share. In that case, IVX IMHO would be valued upon approval of Paxene at ~ $10 to $12/sh. Am I missing something here? Why is this dog sinking like a rock in a dirty toilet? Is BM-S going to file an injunction if Paxene is approved? Jackson ****************************************************************** BM-S exerpt 10Q 11/97 Sales of TAXOL* (R) (paclitaxel), the Company's leading anti-cancer agent, increased 18% to $242. In August 1997, the FDA cleared TAXOL* for use in second-line treatment of AIDS-related Kaposi's sarcoma. *********************************************************************